Condition
Germline BRCA1 Gene Mutation
Total Trials
6
Recruiting
1
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (2)
Trial Status
Active Not Recruiting2
Not Yet Recruiting1
Terminated1
Recruiting1
Unknown1
Clinical Trials (6)
Showing 6 of 6 trials
NCT04090567Phase 2Recruiting
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
NCT07436312Not ApplicableNot Yet Recruiting
Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer
NCT04584255Phase 2Active Not Recruiting
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
NCT04585074Active Not Recruiting
Prospective Study of MAstectomy With Reconstruction Including Robot Endoscopic Surgery
NCT04668521Terminated
Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection
NCT04983628Unknown
Molecular Profiling in Prostate Cancer
Showing all 6 trials